NasdaqGS:WGSHealthcare
GeneDx Holdings (WGS) Returns To US$17.7 Million Quarterly Loss Challenging Bullish Profitability Narrative
GeneDx Holdings (WGS) opened Q1 2026 with recent quarterly revenue of US$120.99 million in Q4 2025 and a basic EPS loss of US$0.61, alongside trailing 12 month revenue of US$427.54 million and a basic EPS loss of US$0.73. Over the last year, revenue has moved from US$95.64 million in Q4 2024 to US$120.99 million in Q4 2025, while quarterly EPS has swung between a profit of US$0.38 in Q2 2025 and losses of up to US$0.61. This sets up an earnings story that investors may review in terms of how...